Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $25.03, giving the company a market capitalization of 142.74B. It carries a P/E multiple of 14.62 and pays a dividend yield of 6.9%.
As of 2025-12-29, Pfizer(PFE) stock has fluctuated between $25.01 and $25.08. The current price stands at $25.03, placing the stock +0.1% above today's low and -0.2% off the high.
Pfizer(PFE) shares are trading with a volume of 175.11K, against a daily average of 54.3M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
PFE News
These income stocks look like smart buys right now. Investing in dividend stocks is a robust strategy for building sustainable wealth through a combination of...
If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today. A $1,000 investment will buy you nearly 20 shares o...
Mixed options sentiment in Pfizer (PFE), with shares up 16c, or 0.66%, near $25.05. Options volume relatively light with 40k contracts traded and calls leading...
Analyst ratings
57%
of 28 ratingsMore PFE News
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season Study Overview: Pfizer (PFE) is running a Pha...
Pfizer Inc. (NYSE:PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In Oct...
Pfizer (PFE) on Tuesday announced that a patient who was taking part in a long-term extension trial for its hemophilia therapy Hympavzi (marstacimab) died after...
Pfizer (PFE) just gave investors a fresh catalyst by unveiling strong Phase 3 data for Padcev plus Keytruda in muscle invasive bladder cancer, a meaningful deve...
